Healthcare management platform Spreemo announces new VP

Spreemo, a New York-based Healthcare management platform, announced this week it has named Daniel Elgort, PhD, its new vice president of healthcare analytics.

Elgort will be in charge of the expansion of Spreemo’s data analytics projects in radiology and other medical disciplines.

“The creation and promotion of objective quality metrics is one of the great challenges and opportunities for reforming our healthcare system,” Elgort said in a statement. “I'm impressed by the strides Spreemo has made in gaining buy-in from payers and the radiology community, and I'm extremely enthusiastic about the opportunity to work with Spreemo and its partners to broaden the scope of its data-rooted infrastructure and make a real impact on patient outcomes.”

“We've been uniquely successful not only in creating objective measures to help identify high-quality radiology providers, but also in receiving widespread support from both the provider and payer communities,” Ron Vianu, Spreemo CEO and co-founder, said in the same statement. “Establishing a currency of quality that all stakeholders--payors and providers alike--can agree upon is fundamental to a more transparent and value-based healthcare system. We're very excited to leverage Daniel's expertise as we expand our efforts to further and analytically refine our understanding of quality in order to address the increasing focus of our partners - that is, improving patient outcomes efficiently across the entire continuum of patient care.”

Elgort was previously director and global lead of healthcare big data analytics research for Philips. He is the primary author of more than 50 peer-reviewed journal articles and abstracts, and holds more than 40 patents.

Spreemo was founded in 2010. Back in June 2015, Pamplona Capital Management announced it was making a “significant investment” in Spreemo.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.